Viz.ai has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its AI algorithm that detects aneurysms on CT angiography (CTA) scans.
Viz Aneurysm is an addition to the company's Viz Intelligent Care Coordination Platform, which offers a number of algorithms for clinical application in ischemic and hemorrhagic stroke, pulmonary embolism, and aortic disease. The platform is covered by Medicare and is installed in more than 1,000 hospitals, Viz.ai said.
Viz Aneurysm was tested in a study published in Stroke last year that found the algorithm was able to detect and measure ruptured and unruptured aneurysms with 94% accuracy in 528 consecutive CTA scans with 674 aneurysms broadly distributed across the cerebral vascular territories.
![Images show the pectoralis muscles of a healthy male individual who never smoked (age, 66 years; height, 178 cm; body mass index [BMI, calculated as weight in kilograms divided by height in meters squared], 28.4; number of cigarette pack-years, 0; forced expiratory volume in 1 second [FEV1], 97.6% predicted; FEV1: forced vital capacity [FVC] ratio, 0.71; pectoralis muscle area [PMA], 59.4 cm2; pectoralis muscle volume [PMV], 764 cm3) and a male individual with a smoking history and chronic obstructive pulmonary disorder (COPD) (age, 66 years; height, 178 cm; BMI, 27.5; number of cigarette pack-years, 43.2, FEV1, 48% predicted; FEV1:FVC, 0.56; PMA, 35 cm2; PMV, 480.8 cm3) from the Canadian Cohort Obstructive Lung Disease (i.e., CanCOLD) study. The CT image is shown in the axial plane. The PMV is automatically extracted using the developed deep learning model and overlayed onto the lungs for visual clarity.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/03/genkin.25LqljVF0y.jpg?auto=format%2Ccompress&crop=focalpoint&dpr=2&fit=crop&h=167&q=70&w=250)
